Antibacterial wound dressing based on advanced nanotechnology to improve the eff...
Antibacterial wound dressing based on advanced nanotechnology to improve the efficiency of wound care
Infected wounds are a major cause of limb amputations among patients with chronic diseases like diabetes. 10mln amputations occur annually causing €100bln additional healthcare costs. During COVID-19 pandemic the number of amputat...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NEXTNANO
NEXT GENERATION NANOPARTICLE-BASED ANTIBACTERIAL TREATMENT F...
75K€
Cerrado
NABIHEAL
ANTIMICROBIAL NANOSTRUCTURED BIOMATERIALS FOR COMPLEX WOUND...
5M€
Cerrado
PID2020-113987RB-I00
APOSITOS TOPICOS FABRICADOS MEDIANTE ELECTROHILADO O POR IMP...
155K€
Cerrado
WoundCure
Personalized Wound Dressings Based on Nanofiber Mats
3M€
Cerrado
BIOCURE
Novel Biomaterial for Improved and Cost efficient Wound Heal...
2M€
Cerrado
PID2020-117900RB-I00
NUEVOS APOSITOS BASADOS EN NANOFIBRAS DE VIDRIO BIOACTIVO PR...
132K€
Cerrado
Información proyecto NANOWOUND
Duración del proyecto: 27 meses
Fecha Inicio: 2022-12-14
Fecha Fin: 2025-03-31
Líder del proyecto
NANORDICA MEDICAL OU
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Infected wounds are a major cause of limb amputations among patients with chronic diseases like diabetes. 10mln amputations occur annually causing €100bln additional healthcare costs. During COVID-19 pandemic the number of amputations rose 10 fold due to low efficacy of current solutions.
Nanordica develops an advanced Antibacterial Wound Dressing (AWD) to prevent and treat wound infections. We have demonstrated that our AWD removes bacterial infection 8x better than current best. Our value propositions are high efficacy and low cost.
Global antibacterial wound dressing market is projected to reach €4.2bln in 2026 at CAGR 5.7%. Our business model is B2B using distributors to reach our customers, i.e. hospitals. We have a priority for intellectual property and initiated a pilot clinical trial at the largest Estonian hospital.
Our mission is to bring AWD to the market to improve the outcome of wound infections, lower healthcare costs and help hundreds of millions of patients.